FDA Surrogate Endpoint Inventory May Lead To Validation Guidance
Executive Summary
FDA is creating an inventory of currently used surrogate endpoints that will be used to help the agency formulate a disease-oriented validation pathway
You may also be interested in...
Cancer Biomarkers Are Opportunity To Predict Tumor Response, Relapse Risk
Oncologic biomarkers could be used to predict tumor response or risk of relapse in certain cancer patients, FDA Deputy Commissioner for Operations Janet Woodcock said March 21
Cancer Biomarkers Are Opportunity To Predict Tumor Response, Relapse Risk
Oncologic biomarkers could be used to predict tumor response or risk of relapse in certain cancer patients, FDA Deputy Commissioner for Operations Janet Woodcock said March 21
FDA Disease Models Will Focus On Areas With Poor R&D Track Records
FDA's disease state modeling efforts may focus on therapeutic areas which traditionally have suboptimal drug development, Office of Clinical Pharmacology & Biopharmaceutics Director Larry Lesko said